Environmental factors are the largest contributors to cardiovascular disease. Here we show that cardiac organoids that incorporate an oxygen-diffusion gradient and that are stimulated with the neurotransmitter noradrenaline model the structure of the human heart after myocardial infarction (by mimicking the infarcted, border and remote zones), and recapitulate hallmarks of myocardial infarction (in particular, pathological metabolic shifts, fibrosis and calcium handling) at the transcriptomic, structural and functional levels. We also show that the organoids can model hypoxia-enhanced doxorubicin cardiotoxicity. Human organoids that model diseases with non-genetic pathological factors could help with drug screening and development.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The main data supporting the results in this study are available within the paper and its Supplementary Information. The raw and analysed datasets generated during the study are available from the corresponding authors on reasonable request. RNA-seq data are available from the NCBI GEO, under the accession numbers GSE113871 and GSE115031.
Custom LabVIEW codes for controlling the custom-built 2PLSM are available from the corresponding author on reasonable request.
Chamberlain, S. J. Disease modelling using human iPSCs. Hum. Mol. Genet. 25, R173–R181 (2016).
Inoue, H., Nagata, N., Kurokawa, H. & Yamanaka, S. iPS cells: a game changer for future medicine. EMBO J. 33, 409–417 (2014).
Clevers, H. Modeling development and disease with organoids. Cell 165, 1586–1597 (2016).
Fatehullah, A., Tan, S. H. & Barker, N. Organoids as an in vitro model of human development and disease. Nat. Cell Biol. 18, 246–254 (2016).
Lancaster, M. A. & Knoblich, J. A. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345, 1247125 (2014).
Driehuis, E. & Clevers, H. CRISPR/Cas 9 genome editing and its applications in organoids. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G257–G265 (2017).
Nie, J. & Hashino, E. Organoid technologies meet genome engineering. EMBO Rep. 18, 367–376 (2017).
Di Lullo, E. & Kriegstein, A. R. The use of brain organoids to investigate neural development and disease. Nat. Rev. Neurosci. 18, 573–584 (2017).
Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407–418 (2018).
Noordhoek, J., Gulmans, V., van der Ent, K. & Beekman, J. M. Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration. Curr. Opin. Pulm. Med. 22, 610–616 (2016).
Nantasanti, S., de Bruin, A., Rothuizen, J., Penning, L. C. & Schotanus, B. A. Concise review: organoids are a powerful tool for the study of liver disease and personalized treatment design in humans and animals. Stem Cells Transl. Med. 5, 325–330 (2016).
Benjamin, E. J. et al. Heart disease and stroke statistics—2017 Update: a report from the American Heart Association. Circulation 135, e146–e603 (2017).
Tiburcy, M. et al. Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair. Circulation 135, 1832–1847 (2017).
Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813–5820 (2013).
Giacomelli, E. et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development 144, 1008–1017 (2017).
Ulmer, B. M. et al. Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes. Stem Cell Rep. 10, 834–847 (2018).
Mills, R. J. et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc. Natl Acad. Sci. USA 114, E8372–E8381 (2017).
Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677–1691 (2013).
Dell’Era, P. et al. Cardiac disease modeling using induced pluripotent stem cell-derived human cardiomyocytes. World J. Stem Cells 7, 329–342 (2015).
Matsa, E. et al. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311–325 (2016).
Burridge, P. W. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547–556 (2016).
Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616–623 (2014).
Ma, Z. et al. Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload. Nat. Biomed. Eng. 2, 955–967 (2018).
Yusuf, S. A 35-year journey to evidence-based medicine: a personal story. Eur. Heart J. 36, 3460–3466 (2015).
Gheorghiade, M. et al. Developing new treatments for heart failure: focus on the heart. Circ. Heart Fail. 9, e002727 (2016).
Fine, B. & Vunjak-Novakovic, G. Shortcomings of animal models and the rise of engineered human cardiac tissue. ACS Biomater. Sci. Eng. 3, 1884–1897 (2017).
Kaye, D. M. & Krum, H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Discov. 6, 127–139 (2007).
Prat-Vidal, C. et al. Identification of temporal and region-specific myocardial gene expression patterns in response to infarction in swine. PLoS ONE 8, e54785 (2013).
Tarnavski, O. et al. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genom. 16, 349–360 (2004).
Chen, T. & Vunjak-Novakovic, G. Human tissue-engineered model of myocardial ischemia-reperfusion injury. Tissue Eng. Part A 25, 711–724 (2018).
Ugolini, G. S. et al. Human cardiac fibroblasts adaptive responses to controlled combined mechanical strain and oxygen changes in vitro. eLife 6, e22847 (2017).
Lowes, B. D. et al. Serial gene expression profiling in the intact human heart. J. Heart Lung Transplant 25, 579–588 (2006).
Stevens, J. L. & Baker, T. K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 14, 162–167 (2009).
Horvath, P. et al. Screening out irrelevant cell-based models of disease. Nat. Rev. Drug Discov. 15, 751–769 (2016).
Page, R. L. II et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134, e32–e69 (2016).
Nunes, S. S. et al. Human stem cell-derived cardiac model of chronic drug exposure. ACS Biomater. Sci. Eng. 3, 1911–1921(2016).
Occhetta, P. et al. A three-dimensional in vitro dynamic micro-tissue model of cardiac scar formation. Integr. Biol. 10, 174–183 (2018).
Sadeghi, A. H. et al. Engineered 3D cardiac fibrotic tissue to study fibrotic remodeling. Adv. Healthc. Mater. 6, 1601434 (2017).
van Spreeuwel, A. C. C. et al. Mimicking cardiac fibrosis in a dish: fibroblast density rather than collagen density weakens cardiomyocyte function. J. Cardiovasc. Transl. Res. 10, 116–127 (2017).
Zhao, H. et al. Microengineered in vitro model of cardiac fibrosis through modulating myofibroblast mechanotransduction. Biofabrication 6, 045009 (2014).
Radisic, M. et al. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol. Bioeng. 93, 332–343 (2006).
Lymperopoulos, A., Rengo, G. & Koch, W. J. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739–753 (2013).
Richards, D. J. et al. Inspiration from heart development: biomimetic development of functional human cardiac organoids. Biomaterials 142, 112–123 (2017).
Frangogiannis, N. G. Pathophysiology of myocardial Infarction. Compr. Physiol. 5, 1841–1875 (2015).
Brown, D. A. et al. Analysis of oxygen transport in a diffusion-limited model of engineered heart tissue. Biotechnol. Bioeng. 97, 962–975 (2007).
Davis, B. H. et al. Effects of myocardial infarction on the distribution and transport of nutrients and oxygen in porcine myocardium. J. Biomech. Eng. 134, 101005 (2012).
Semenza, G. L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim. Biophys. Acta 1813, 1263–1268 (2011).
Beeson, C. C., Beeson, G. C. & Schnellmann, R. G. A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal. Biochem. 404, 75–81 (2010).
Graham, R. M. et al. A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J. Exp. Biol. 207, 3189–3200 (2004).
Kligfield, P., Horner, H. & Brachfeld, N. A model of graded ischemia in the isolated perfused rat heart. J. Appl. Physiol. 40, 1004–1008 (1976).
Valvona, C. J., Fillmore, H. L., Nunn, P. B. & Pilkington, G. J. The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor. Brain Pathol. 26, 3–17 (2016).
Bonen, A. Lactate transporters (MCT proteins) in heart and skeletal muscles. Med. Sci. Sports Exerc. 32, 778–789 (2000).
Draoui, N. & Feron, O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis. Model. Mech. 4, 727–732 (2011).
Chen, W. & Frangogiannis, N. G. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim. Biophys. Acta 1833, 945–953 (2013).
van den Borne, S. W. et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J. Am. Coll. Cardiol. 52, 2017–2028 (2008).
Mewton, N., Liu, C. Y., Croisille, P., Bluemke, D. & Lima, J. A. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 57, 891–903 (2011).
Messroghli, D. R. et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn. Reson. Med. 58, 34–40 (2007).
Ho, C. Y. et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N. Engl. J. Med. 363, 552–563 (2010).
Weber, K. T. et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ. Res. 62, 757–765 (1988).
Yong, K. W. et al. Mechanoregulation of cardiac myofibroblast differentiation: implications for cardiac fibrosis and therapy. Am. J. Physiol. Heart Circ. Physiol. 309, H532–H542 (2015).
Trickey, W. R., Lee, G. M. & Guilak, F. Viscoelastic properties of chondrocytes from normal and osteoarthritic human cartilage. J. Orthop. Res. 18, 891–898 (2000).
Richardson, W. J., Clarke, S. A., Quinn, T. A. & Holmes, J. W. Physiological implications of myocardial scar structure. Compr. Physiol. 5, 1877–1909 (2015).
Herum, K. M., Choppe, J., Kumar, A., Engler, A. J. & McCulloch, A. D. Mechanical regulation of cardiac fibroblast profibrotic phenotypes. Mol. Biol. Cell 28, 1871–1882 (2017).
Lou, Q., Janardhan, A. & Efimov, I. R. Remodeling of calcium handling in human heart failure. Adv. Exp. Med. Biol. 740, 1145–1174 (2012).
Bhar-Amato, J., Davies, W. & Agarwal, S. Ventricular arrhythmia after acute myocardial infarction: ‘the perfect storm’. Arrhythm. Electrophysiol. Rev. 6, 134–139 (2017).
Huisken, J. & Stainier, D. Y. Selective plane illumination microscopy techniques in developmental biology. Development 136, 1963–1975 (2009).
Truong, T. V., Supatto, W., Koos, D. S., Choi, J. M. & Fraser, S. E. Deep and fast live imaging with two-photon scanned light-sheet microscopy. Nat. Methods 8, 757–760 (2011).
Morita, N., Mandel, W. J., Kobayashi, Y. & Karagueuzian, H. S. Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J. Arrhythm. 30, 389–394 (2014).
Duan, Q. et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci. Transl. Med. 9, eaah5084 (2017).
Mehta, L. S. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137, e30–e66 (2018).
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D. & Denberg, T. D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 13, R64 (2011).
Salz, T. et al. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors. J. Clin. Oncol. 35, 3837–3843 (2017).
Narayan, H. K. et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135, 1397–1412 (2017).
Arafa, M. H., Mohammad, N. S., Atteia, H. H. & Abd-Elaziz, H. R. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J. Physiol. Biochem. 70, 701–711 (2014).
Torti, F. M. et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 46, 3722–3727 (1986).
Mortensen, S. A., Olsen, H. S. & Baandrup, U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br. Heart J. 55, 274–282 (1986).
Tham, E. B. et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J. Cardiovasc. Magn. Reson. 15, 48 (2013).
Zamorano, J. L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 37, 2768–2801 (2016).
Stevens, K. R. & Murry, C. E. Human pluripotent stem cell-derived engineered tissues: clinical considerations. Cell Stem Cell 22, 294–297 (2018).
Forte, E., Furtado, M. B. & Rosenthal, N. The interstitium in cardiac repair: role of the immune-stromal cell interplay. Nat. Rev. Cardiol. 15, 601–616 (2018).
Leopold, J. A. & Loscalzo, J. Emerging role of precision medicine in cardiovascular disease. Circ. Res. 122, 1302–1315 (2018).
Santolini, M. et al. A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure. NPJ Syst. Biol. Appl. 4, 12 (2018).
van den Heuvel, N. H., van Veen, T. A., Lim, B. & Jonsson, M. K. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. J. Mol. Cell. Cardiol. 67, 12–25 (2014).
Davis-Turak, J. et al. Genomics pipelines and data integration: challenges and opportunities in the research setting. Expert Rev. Mol. Diagn. 17, 225–237 (2017).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Draghici, S. et al. A systems biology approach for pathway level analysis. Genome Res. 17, 1537–1545 (2007).
Hannenhalli, S. et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 114, 1269–1276 (2006).
Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 1–25 (2004).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23, 1846–1847 (2007).
Jol, S. J. Make a Venn diagram stefanjol.nl https://www.stefanjol.nl/venny (2015).
Ignatchenko, V., Ignatchenko, A., Sinha, A., Boutros, P. C. & Kislinger, T. VennDIS: a JavaFX-based Venn and Euler diagram software to generate publication quality figures. Proteomics 15, 1239–1244 (2015).
Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305–W311 (2009).
Yang, K. C. et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129, 1009–1021 (2014).
Ounzain, S. et al. Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur. Heart J. 36, 353–368 (2015).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Huang, S., Heikal, A. A. & Webb, W. W. Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein. Biophys. J. 82, 2811–2825 (2002).
Russell, S., Wojtkowiak, J., Neilson, A. & Gillies, R. J. Metabolic profiling of healthy and cancerous tissues in 2D and 3D. Sci. Rep. 7, 15285 (2017).
Sato, M., Theret, D. P., Wheeler, L. T., Ohshima, N. & Nerem, R. M. Application of the micropipette technique to the measurement of cultured porcine aortic endothelial cell viscoelastic properties. J. Biomech. Eng. 112, 263–268 (1990).
Theret, D. P., Levesque, M. J., Sato, M., Nerem, R. M. & Wheeler, L. T. The application of a homogeneous half-space model in the analysis of endothelial cell micropipette measurements. J. Biomech. Eng. 110, 190–199 (1988).
Edelstein, A. D. et al. Advanced methods of microscope control using muManager software. J. Biol. Methods 1, e10 (2014).
We thank W. da Silveira for insights into microarray, RNA-seq and GSEA analysis and the staff of the laboratory of M. Morad for help with GCaMP6 labelling. The work was supported by the National Institutes of Health (R01 HL133308, 8P20 GM103444, U54 GM104941), National Institute of General Medical Sciences (P20GM-103499), start-up funds from Clemson University, the National Science Foundation (NSF; EPS-0903795, 1539034), the NIH Cardiovascular Training Grant (T32 HL007260), SCTR Institute CTSA NIH/NCATS (UL1TR001450) and US Department of Veterans Affairs Merit Review (I01 BX002327); and NIH grants (R03 DE018741 and R01 DE021134 to H.Y). G.H. acknowledges support from NIH/NIDA (1U01DA045300-01A1). This study used the services of the Morphology, Imaging and Instrumentation Core, which is supported by NIH-NIGMS P30 GM103342 to the South Carolina COBRE for Developmentally Based Cardiovascular Diseases and was supported in part by the Genomics Shared Resource, Hollings Cancer Center, and the Medical University of South Carolina (P30 CA138313). The Bioenergetics Profiling Core is supported by the COBRE in Redox, Oxidant Balance and Stress Signalling (NIH/NIGMS P20 GM103542). We dedicate this work to C.C.B.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary figures and legends for Supplementary Videos 1–10 and Supplementary Tables 1–7.
GO terms and P values for the overlapping regions of the Venn diagrams of DE genes in mice, pigs, humans and human cardiac organoids with ischaemic cardiac injury.
Top 35 GO terms.
Metabolic-pathway gene sets.
Fibrosis-related gene sets.
Significant P values in the radial-density plots of Figs. 4f, 6b and 7c.
Calcium-handling-related gene sets.
P values from the two-way ANOVA with post hoc Tukey tests in Fig. 7e.
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the organoid for control organoids at day 10.
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the organoid for infarct organoids at day 10.
Bright-field observations of synchronized control organoids at day 10.
Bright-field observations of unsynchronized infarct organoids at day 10.
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the spheroid for infarct CM spheroids at day 10.
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the organoid for control organoids at day 10 (derived from cells for donor B).
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the organoid for infarct organoids at day 10 (derived from cells for donor B).
Bright-field observations of synchronized control organoids at day 10 (derived from cells for donor B).
Bright-field observations of unsynchronized infarct organoids at day 10 (derived from cells for donor B).
Customized two-photon scanned light-sheet microscopy of more than 50 μm below the surface of the organoid for infarct organoids at day 10 (with treatment with an anti-fibrotic drug candidate).
About this article
Cite this article
Richards, D.J., Li, Y., Kerr, C.M. et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat Biomed Eng 4, 446–462 (2020). https://doi.org/10.1038/s41551-020-0539-4
Opportunities and challenges in cardiac tissue engineering from an analysis of two decades of advances
Nature Biomedical Engineering (2022)
Microsystems & Nanoengineering (2022)
Current Cardiology Reports (2022)
Stem Cell Reviews and Reports (2022)
Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?
Current Cardiology Reports (2022)